Form 4: Tarsus CMO Acquires Shares via RSU Vesting

Tarsus Pharmaceuticals' Chief Medical Officer, Elizabeth Yeu Lin, acquired 2,511 shares of common stock through the settlement of vested Restricted Stock Units.

Summary

• Elizabeth Yeu Lin, Chief Medical Officer of Tarsus Pharmaceuticals, Inc., acquired 2,511 shares of common stock.
• The acquisition occurred on March 15, 2026, through the settlement of vested Restricted Stock Units (RSUs).
• Following this transaction, Ms. Lin directly beneficially owns 24,452 shares of common stock.
• She also indirectly owns 6,360 shares via her spouse's Roth IRA and 12,040 shares via a 401(k) Plan.
• An additional 7,534 Restricted Stock Units remain beneficially owned directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a routine compensation event and an increase in insider ownership, which can be seen as a sign of confidence, though it's not a discretionary open-market purchase.

Positives

• Chief Medical Officer Elizabeth Yeu Lin increased her direct beneficial ownership of common stock by 2,511 shares.
• The transaction was part of a pre-arranged Rule 10b5-1(c) plan, indicating planned equity management.

Future Outlook

The filing indicates future vesting of 7,534 Restricted Stock Units on March 15th of 2027, 2028, and 2029, contingent on the Chief Medical Officer's continuous service.

Industry Context

StockSavvy.ai notes that insider transactions, particularly acquisitions through RSU vesting, are common for executives in the pharmaceutical industry as part of their compensation structure. This type of transaction reflects the ongoing equity compensation plans designed to align executive interests with shareholder value over the long term.

Comparison to Industry Standards

• This transaction is standard practice for executive compensation in the biotechnology and pharmaceutical sectors, where Restricted Stock Units are a common form of long-term incentive.
• Companies like Pfizer, Moderna, and Johnson & Johnson frequently utilize similar equity compensation plans for their executives, with vesting schedules tied to continued employment.
• The specific number of shares is relative to the executive's compensation package and the company's overall equity plan.

Stakeholder Impact

• Shareholders: Increased insider ownership may signal management's continued alignment with shareholder interests.
• Employees: The RSU vesting demonstrates the company's commitment to its equity compensation plans for key personnel.

Next Steps

• Future vesting of 25% of the original RSU grant on March 15, 2027.
• Future vesting of 25% of the original RSU grant on March 15, 2028.
• Future vesting of 25% of the original RSU grant on March 15, 2029.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled vesting and settlement of Restricted Stock Units for a Chief Medical Officer. While it increases insider ownership, it is not a discretionary open-market purchase and therefore does not typically signal a strong change in investment thesis. It's an expected compensation event, warranting a "hold" as it doesn't provide new information to alter an existing investment stance.

Keywords

Tarsus Pharmaceuticals, TARS, Elizabeth Yeu Lin, Chief Medical Officer, CMO, SEC Form 4, Insider Trading, Stock Ownership, Restricted Stock Units, RSU, Equity Compensation, Rule 10b5-1